Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-19

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
It is hypothesized that immunotherapy with off-the-shelf NK cells (KDS-1000) early in the course of COVID-19 disease is safe and may augment innate immunity, thereby limiting disease progression and improving survival.
Epistemonikos ID: cec0c570b6795805cf6320aa2eae64b8b676dc3e
First added on: Mar 16, 2021